β-lactamase inhibitor and use thereof

1. A compound of formula (I), or an ester, a stereoisomer, or a pharmaceutically acceptable salt thereof:

wherein W 1 is selected from an optionally substituted 5- or 6-membered heteroaromatic ring containing O, N, and/or S, and —C(O)—; (i) when W 1 is the optionally substituted 5- or 6-membered heteroaromatic ring containing O, N, and/or S, W 1 is optionally substituted with C 1 -C 12 alkyl,

W 2 is selected from:

(a) H

(b)

 wherein R 1 is selected from

 R 2 , R 3 , R 4 , R 4 ′, R 5 , and R 6 are each independently selected from H, C 1 -C 12 alkyl, amino C 1 -C 12 alkyl, C 1 -C 12 alkylamino C 1 -C 12 alkyl,

 Ra and Rb are each independently selected from H, C 1 -C 12 alkyl, C 3 -C 8 cycloalkyl, OH, —OC 1 -C 12 alkyl, —NH 2 , —NHC 1 -C 12 alkyl, —N(C 1 -C 12 alkyl) 2 , —SH, —SC 1 -C 12 alkyl, —S(O)C 1 -C 12 alkyl, —S(O 2 )C 1 -C 12 alkyl, and —SO 3 H; R 7 and R 7 ′ are each independently selected from —NH 2 , —NHC 1 -C 12 alkyl, —N(C 1 -C 12 alkyl) 2 , —OC 1 -C 12 alkyl, and —SC 1 -C 12 alkyl; R 8 and R 8 ′ are each independently selected from NH, —N(C 1 -C 12 alkyl), O, and S; R 9 and R 9 ′ are each independently selected from —NH—, —N(C 1 -C 12 alkyl)-, —O—, and —S—; Z 1 is selected from CR 10 R 11 , and NR 12 ; R 10 , R 11 , and R 12 are each independently selected from H, NH 2 ,

 R 13 and R 15 are each independently selected from —NH 2 , —NHC 1 -C 12 alkyl, —N(C 1 -C 12 alkyl) 2 , —OC 1 -C 12 alkyl, and —SC 1 -C 12 alkyl; R 14 and R 16 are each independently selected from NH, NC 1 -C 12 alkyl, O, and S; R 17 is selected from —NH—, —N(C 1 -C 12 alkyl)-, —O—, and —S—; i, j, k, l, m, n, p, q, r, and s are each independently selected from 0, 1, 2, 3, 4, 5, and 6, provided that q and r are not both 0; R 1 ′ is selected from H, C 1 -C 12 alkyl, C 3 -C 8 cycloalkyl, OH, —OC 1 -C 12 alkyl, —NH 2 , —NHC 1 -C 12 alkyl, —N(C 1 -C 12 alkyl) 2 , —SH, —SC 1 -C 12 alkyl, —S(O)C 1 -C 12 alkyl, —S(O 2 )C 1 -C 12 alkyl, and —SO 3 H;

(c)

 wherein Z 2 is selected from CR 18 R 19 , and NR 20 ; R 18 , R 19 and R 20 are each independently selected from H, NH 2 , and

 R 21 is selected from —NH 2 , —NHC 1 -C 12 alkyl, —N(C 1 -C 12 alkyl) 2 , —OC 1 -C 12 alkyl, and —SC 1 -C 12 alkyl; R 22 is selected from NH, NC 1 -C 12 alkyl, O, and S; t, u and w are each independently selected from 0, 1, 2, 3, 4, 5, and 6, provided that t and u are not both 0;

(d)

 wherein Z 3 and Z 4 are each independently selected from —NR 25 —, and —O—; R 23 and R 24 are each independently selected from H and C 1 -C 12 alkyl, or R 23 and R 24 together form ═O or ═NH; R 25 is selected from H, amino C 1 -C 12 alkyl, and C 1 -C 12 alkylamino C 1 -C 12 alkyl;

(ii) when W 1 is selected from —C(O)—,

W 2 is selected from —OR 26 and —NHR 27 , wherein R 26 and R 27 are each independently selected from H, C 1 -C 12 alkyl, and

 Z 5 is selected from CR 28 R 29 , and NR 30 ; R 28 , R 29 , and R 30 are each independently selected from H, NH 2 , and

 R 31 is selected from —NH 2 , —NHC 1 -C 12 alkyl, —N(C 1 -C 12 alkyl) 2 , —OC 1 -C 12 alkyl, and —SC 1 -C 12 alkyl; R 32 is selected from NH, NC 1 -C 12 alkyl, O, and S; x, y and z are each independently selected from 0, 1, 2, 3, 4, 5, and 6, provided that x and y are not both 0;

W 3 is selected from —SO 3 M, —OSO 3 M, —OSO 2 NH 2 , —OPO 3 M, —OCR 33 R 34 CO 2 M, —OCR 35 R 36 SO 3 M, and —OCR 37 R 38 PO 3 M; wherein M is selected from H and a pharmaceutically acceptable cation; R 33 , R 34 , R 35 , R 36 , R 37 , and R 38 are each independently selected from H, C 1 -C 12 alkyl, and halogen.

2. The compound, or the ester, the stereoisomer, or the pharmaceutically acceptable salt thereof according to claim 1 , wherein the compound of formula (I) is:

wherein W 1 , W 2 , and W 3 are defined in formula (I).

3. The compound, or the ester, the stereoisomer, or the pharmaceutically acceptable salt thereof according to claim 2 , wherein,

W 1 is selected from an optionally substituted 5- or 6-membered heteroaromatic ring containing O, N, and/or S;

W 2 is selected from:

(a) H

(b)

 wherein R 1 is selected from

 R 2 , R 3 , R 4 , R 4 ′, R 5 , and R 6 are each independently selected from H, C 1 -C 12 alkyl, amino C 1 -C 12 alkyl, C 1 -C 12 alkylamino C 1 -C 12 alkyl,

 Ra and Rb are each independently selected from H, C 1 -C 12 alkyl, OH, —OC 1 -C 12 alkyl, —NH 2 , —NHC 1 -C 12 alkyl, —N(C 1 -C 12 alkyl) 2 , —SH, —SC 1 -C 12 alkyl, —S(O)C 1 -C 12 alkyl, —S(O 2 )C 1 -C 12 alkyl, and —SO 3 H; R 7 and R 7 ′ are each independently selected from —NH 2 , —NHC 1 -C 12 alkyl, —N(C 1 -C 12 alkyl) 2 , —OC 1 -C 12 alkyl, and —SC 1 -C 12 alkyl; R 8 and R 8 ′ are each independently selected from NH, —NC 1 -C 12 alkyl, O, and S; R 9 and R 9 ′ are each independently selected from —NH—, —N(C 1 -C 12 alkyl)-, —O—, and —S—; Z 1 is selected from CR 10 R 11 and NR 12 ; R 10 , R 11 and R 12 are each independently selected from H, NH 2 ,

 R 13 and R 15 are each independently selected from —NH 2 , —NHC 1 -C 12 alkyl, —N(C 1 -C 12 alkyl) 2 , —OC 1 -C 12 alkyl, and —SC 1 -C 12 alkyl; R 14 and R 16 are each independently selected from NH, NC 1 -C 12 alkyl, O, and S; R 17 is selected from —NH—, —N(C 1 -C 12 alkyl)-, —O—, and —S—; and i, j, k, l, m, n, p, q, r, and s are each independently selected from 0, 1, 2, 3, 4, 5, and 6, provided that q and r are not both 0;

R 1 ′ is selected from H, C 1 -C 12 alkyl, C 3 -C 8 cycloalkyl, OH, —OC 1 -C 12 alkyl, —NH 2 , —NHC 1 -C 12 alkyl, —N(C 1 -C 12 alkyl) 2 , —SH, —SC 1 -C 12 alkyl, —S(O)C 1 -C 12 alkyl, —S(O 2 )C 1 -C 12 alkyl, and —SO 3 H;

(c)

 wherein Z 2 is selected from CR 18 R 19 , and NR 20 ; R 18 , R 19 and R 20 are each independently selected from H, NH 2 , and

 R 21 is selected from —NH 2 , —NHC 1 -C 12 alkyl, —N(C 1 -C 12 alkyl) 2 , —OC 1 -C 12 alkyl, and —SC 1 -C 12 alkyl; R 22 is selected from NH, NC 1 -C 12 alkyl, O, and S; t, u and w are each independently selected from 0, 1, 2, 3, 4, 5, and 6, provided that t and u are not both 0;

(d)

 wherein Z 3 and Z 4 are each independently selected from —NR 25 —, and —O—; R 23 and R 24 are each independently selected from H and C 1 -C 12 alkyl, or R 23 and R 24 together form ═O or ═NH; R 25 is selected from H, amino C 1 -C 12 alkyl, and C 1 -C 12 alkylamino C 1 -C 12 alkyl.

4. The compound, or the ester, the stereoisomer, or the pharmaceutically acceptable salt thereof according to claim 2 , wherein,

W 1 is —C(O)—;

W 2 is selected from —OR 26 , and —NHR 27 , wherein R 26 and R 27 are each independently selected from H, C 1 -C 12 alkyl, and

 Z 5 is selected from CR 28 R 29 , and NR 30 ; R 28 , R 29 , and R 30 are each independently selected from H, NH 2 , and

 R 31 is selected from —NH 2 , —NHC 1 -C 12 alkyl, —N(C 1 -C 12 alkyl) 2 , —OC 1 -C 12 alky, and —SC 1 -C 12 alkyl; R 32 is selected from NH, NC 1 -C 12 alkyl, O, and S; and x, y and z are each independently selected from 0, 1, 2, 3, 4, 5, and 6, provided that x and y are not both 0.

5. The compound, or the ester, the stereoisomer, or the pharmaceutically acceptable salt thereof according to claim 1 , wherein W 1 is selected from:

X is selected from O, S, and NH; Y and Z are each independently selected from CH and N; and W 1 is optionally substituted with C 1 -C 12 alkyl.

6. The compound, or the ester, the stereoisomer, or the pharmaceutically acceptable salt thereof according to claim 1 , wherein W 1 is selected from a furan ring, a pyrrole ring, a pyrazole ring, an imidazole ring, a triazole ring, a thiophene ring, a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, a 1,2,4-oxadiazole ring, a 1,3,4-oxadiazole ring, a pyridine ring, pyrimidyl, a triazine ring, a pyrazine ring, a tetrazole ring, a pyridazine ring, and a thiadiazole ring;

M is selected from H, sodium ion, potassium ion, calcium ion, magnesium ion, NH 4 + , and N(C 1 -C 12 alkyl) 4 + .

7. The compound or the pharmaceutically acceptable salt thereof according to claim 6 , wherein W 1 is selected from an oxazole ring, an isoxazole ring, a 1,2,4-oxadiazole ring, and a 1,3,4-oxadiazole ring.

8. The compound or the pharmaceutically acceptable salt thereof according to claim 7 , wherein W 1 is selected from

9. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , which is selected from:

(1R,4S)-4-(1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(aminomethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(guanidinomethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-aminoethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-guanidinoethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

sodium (1R,4S)-4-(5-(3-aminopropyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(4-aminobutyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-iminoimidazolidin-4-yl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-amino-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-guanidyl-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((R)-2-guanidyl-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((S)-2-guanidyl-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(1-(guanidinomethyl)cyclopropyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((azetidin-3-ylamino)methyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(guanidinomethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((1-methylguanidino)methyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(aminomethyl)-isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((methylamino)methyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-guanidinoethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-(1-methylguanidino)ethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-guanidyl-1-hydroxyethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((S)-2-guanidyl-1-hydroxyethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((R)-2-guanidyl-1-hydroxyethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-aminoethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-(methylamino)ethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-6-oxo-4-(5-(piperidin-4-yl)isoxazol-3-yl)-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-6-oxo-4-(5-(piperidin-3-yl)isoxazol-3-yl)-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-6-oxo-4-(5-(pyrrolidin-3-yl)isoxazol-3-yl)-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-6-oxo-4-(5-(2-(piperidin-4-ylamino)ethyl)isoxazol-3-yl)-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-((1-amidinopiperidin-4-yl)amino)ethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((1S,3R)-3-aminocyclobutyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((1R,3S)-3-aminocyclobutyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((1R,3S)-3-aminocyclopentyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((1R,3R)-3-aminocyclopentyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(((1R,3R)-3-aminocyclobutyl)methyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(((1S,3S)-3-aminocyclobutyl)methyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((1-aminocyclopropyl)methyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((1-(methylamino)cyclopropyl)methyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(azetidin-3-ylmethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-(methylamino)ethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((azetidin-3-ylamino)methyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(azetidin-3-ylmethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((azetidin-3-yloxy)methyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(((1-amidinoazetidin-3-yl)amino)methyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(3-aminocyclobutyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((1S,3S)-3-aminocyclobutyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((1R,3R)-3-aminocyclobutyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-((2-guanidinoethyl)amino)ethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-6-oxo-4-(piperidin-4-ylaminoformyl)-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-6-oxo-4-(pyrrolidin-3-ylaminoformyl)-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(azetidin-3-ylaminoformyl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((S)-1-hydroxy-2-((2-(methylamino)ethyl)amino)ethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((S)-2-((2-aminoethyl)amino)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((S)-2-iminoimidazolidin-4-yl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((R)-2-iminoimidazolidin-4-yl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

2-(((1R,4S)-4-(5-(aminomethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl)oxy)acetate;

2-(((1R,4S)-4-(5-(((tert-butoxycarbonyl)amino)methyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl)oxy)acetate;

2-(((1R,4S)-4-(5-(aminomethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl)oxy)-2,2-difluoroacetate;

2-(((1R,4S)-4-(5-(((tert-butoxycarbonyl)amino)methyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl)oxy)-2,2-difluoroacetate;

(1R,4S)-4-(5-((1S,3R)-3-guanidinocyclobutyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(1-hydroxy-2-((2-(methylamino)ethyl)amino)ethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((S)-1-hydroxy-2-((2-(methylamino)ethyl)amino)ethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((R)-1-hydroxy-2-((2-(methylamino)ethyl)amino)ethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-((2-aminoethyl)amino)-1-hydroxyethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((S)-2-((2-aminoethyl)amino)-1-hydroxyethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((R)-2-((2-aminoethyl)amino)-1-hydroxyethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-((2-guanidinoethyl)amino)-1-hydroxyethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((S)-2-((2-guanidinoethyl)amino)-1-hydroxyethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((R)-2-((2-guanidinoethyl)amino)-1-hydroxyethyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((1-hydroxy-2-((2-methylamino)ethyl)amino)ethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((R)-1-hydroxy-2-((2-(methylamino)ethyl)amino)ethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-((2-aminoethyl)amino)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((R)-2-((2-aminoethyl)amino)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-((2-guanidinoethyl)amino)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((S)-2-((2-guanidinoethyl)amino)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((R)-2-((2-guanidinoethyl)amino)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-(azetidin-3-ylamino)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(1-hydroxy-2-(methylamino)ethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(1-hydroxy-2-(pyrrolidin-3-ylamino)ethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-(dimethylamino)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(hydroxy(pyrrolidin-2-yl)methyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

2-hydroxy-N,N,N-trimethyl-2-(5-((1R,4S)-6-oxo-7-(sulfooxy)-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropane]-4-yl)-1,3,4-oxadiazol-2-yl)ethan-1-ammonium;

(1R,4S)-4-(5-(1-hydroxy-2-(piperidin-4-ylamino)ethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(4-hydroxypiperidin-4-yl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(1-amidinopiperidin-4-yl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-6-oxo-4-(5-(piperazin-1-yl)isoxazol-3-yl)-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-6-oxo-4-(5-(2-oxopiperazine-1-yl)isoxazol-3-yl)-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(L-prolyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((S)-2-((2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

2-(((2S)-2-hydroxy-2-(5-((1R,4S)-6-oxo-7-(sulfooxy)-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropane]-4-yl)-1,3,4-oxadiazol-2-yl)ethyl)amino)-N,N,N-trimethylethan-1-ammonium;

(1R,4S)-6-oxo-4-(5-(2-oxoimidazolidine-4-yl)-1,3,4-oxadiazol-2-yl)-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-6-oxo-4-(5-(2-oxooxazolidine-5-yl)-1,3,4-oxadiazol-2-yl)-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-6-oxo-4-(5-(2-oxooxazolidine-4-yl)-1,3,4-oxadiazol-2-yl)-5,7-diazaspiro[bicycle [3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(2-imino-1-((methylamino)methyl)imidazolidin-4-yl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-(1-((dimethylamino)methyl)-2-iminoimidazolidin-4-yl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

1-(2-imino-4-(5-((1R,4S)-6-oxo-7-(sulfooxy)-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropane]-4-yl)-1,3,4-oxadiazol-2-yl)imidazolidin-1-yl)-N,N,N-trimethylmethylammonium;

(1R,4S)-4-(5-(2-imino-1-((methylamino)methyl)-5-oxoimidazolidin-4-yl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropane]-7-yl sulfate;

(1R,4S)-4-(5-(5-hydroxy-2-imino-1-((methylamino)methyl)imidazolidin-4-yl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropane]-7-yl sulfate;

(1R,4S)-4-(5-(3-((methylamino)methyl)-2-oxooxazolidine-4-yl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropane]-7-yl sulfate;

(1R,4S)-4-(5-(1-(aminomethyl)-2-iminoimidazolidin-4-yl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropane]-7-yl sulfate;

(1R,4S)-4-(5-(5-amino-2-iminoimidazolidin-4-yl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropane]-7-yl sulfate;

(1R,4S)-4-(5-(2-imino-5-(methylamino)imidazolidin-4-yl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropane]-7-yl sulfate;

(1R,4S)-4-(5-(5-(dimethylamino)-2-iminoimidazolidin-4-yl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl sulfate;

(1R,4S)-4-(5-((R)-2-amino-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropane]-7-yl sulfate;

(1R,4S)-4-(5-((S)-2-amino-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro [bicyclo[3.2.1]octane-2,1′-cyclopropane]-7-yl sulfate;

(1R,4S)-4-(5-((S)-1-hydroxy-2-(methylamino)ethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropane]-7-yl sulfate;

(1R,4S)-4-(5-((S)-2-(dimethylamino)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropane]-7-yl sulfate;

2-(((1R,4S)-4-(5-(aminomethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl)oxy)acetate;

2-(((1R,4S)-4-(5-(((tert-butoxycarbonyl)amino)methyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl)oxy)acetate;

2-(((1R,4S)-4-(5-(aminomethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl)oxy)-2,2-difluoroacetate;

2-(((1R,4S)-4-(5-(((tert-butoxycarbonyl)amino)methyl)isoxazol-3-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1′-cyclopropan]-7-yl)oxy)-2,2-difluoroacetate.

10. A method of preparation for the compound of formula (I) of claim 1 , wherein W 1 in the compound of formula (I) is selected from a 1,3,4-oxadiazole ring; the method comprising:

step 1: the intermediate 1 and hydrazide are subjected to condensation under a basic condition to give the intermediate 2;

Step 2: the intermediate 2 is subjected to cyclization to give the intermediate 3;

step 3: the protecting group P in the intermediate 3 is selectively removed to give the intermediate 4;

step 4: the intermediate 4 reacts with SO 3 under a basic condition to give the intermediate 5;

step 5: the protecting group P′ in the intermediate 5 is removed to give the product 6;

wherein, P is a hydroxyl protecting group, P′ is a hydroxyl or amine protecting group, and W 2 is defined in formula (I).

11. A pharmaceutical composition comprising the compound according to claim 1 , and a pharmaceutically acceptable excipient.

12. The pharmaceutical composition according to claim 11 , further comprising one or more β-lactam antibiotics.

13. The pharmaceutical composition according to claim 12 , wherein the β-lactam antibiotic is selected from a penicillin antibiotic, a cephalosporin antibiotic, a monobactam antibiotic, a carbapenem antibiotic, and a penemase inhibitor.

14. A method of treating a disease caused by a bacterial infection in a subject, comprising administration of a therapeutically effective amount of the compound according to claim 1 .

15. The method according to claim 14 , wherein the method further comprises administration of a β-lactam antibiotic.

16. The method according to claim 14 , wherein the bacterium is selected from one or more of Citrobacter spp., Citrobacter freundii, Enterobacter cloacae, Klebsiella pneumoniae, Escherichia coli, Proteus vulgaris, Salmonella spp., Serratia marcescens, Shigella spp., Pseudomonas aeruginosa, Moraxella mucositis, Neisseria gonorrhoeae, Neisseria meningitidis, Acinetobacter spp., Burkholderia spp., Campylobacter spp., Helicobacter pylori, Vibrio cholerae, Klebsiella pneumoniae, Haemophilus influenzae, Mycobacterium avium complex, Mycobacterium abscessus, Mycobacterium kansasii, Mycobacterium ulcerosa, Chlamydophila pneumoniae, Chlamydia trachomatis , β-hemolytic Streptococcus, Acinetobacter baumannii, Pseudomonas pyocyaneum, Pseudomonas aeruginosa, Bacteroides fragilis, Bacillus cereus , and Stenotrophomonas maltophilia.

17. The method according to claim 14 , wherein the disease is selected from one or more of respiratory tract infection, urinary tract infection, central nervous system infection, ear infection, pleuropneumoniae and bronchial infection, intra-abdominal infection, cardiovascular infection, skin or soft tissue infections, bone and joint infections, genital infection, eye infection, pharyngeal infection, and oral infection.

18. The method according to claim 17 , wherein the disease is selected from one or more of upper respiratory tract infection, lower respiratory tract infection, tracheitis, bronchitis, pneumonia, pulmonary tuberculosis, pharyngitis, complicated urinary tract infection, non-complicated urinary tract infections, cystitis, pyelonephritis, encephalitis, meningitis, brain abscess, otitis externa, otitis media, blood infection, endocarditis, myocarditis, pericarditis, arthritis, osteomyelitis, genital ulceration, vaginitis, cervicitis, conjunctivitis, keratitis, endophthalmitis, pharyngitis, and gingivitis.

19. The method according to claim 18 , wherein the blood infection is sepsis or bacteremia.